SLC27A3 Antibody

What is SLC27A3 and what are its common alternative names in scientific literature?

SLC27A3 (Solute Carrier Family 27 Member 3) is also known by several other names in scientific literature, including FATP-3 (Fatty acid transport protein 3), Long-chain fatty acid transport protein 3, and VLCS-3 (Very long-chain acyl-CoA synthetase homolog 3) . This protein plays a significant role in long-chain fatty acid transport across the plasma membrane and is involved in fatty acid metabolism . Understanding the various nomenclatures is essential when conducting literature reviews or designing experiments targeting this protein, as different research groups may refer to it using different terminology in their publications.

What are the primary applications for SLC27A3 antibodies in research?

SLC27A3 antibodies are versatile research tools with multiple validated applications. Based on manufacturer specifications, these antibodies can be used for Western blotting (at concentrations of 0.04-0.4 μg/mL or 0.4 μg/mL depending on the specific antibody), immunohistochemistry (IHC) on both fresh tissues and paraffin-embedded sections (at dilutions of 1:50-1:200 or 1:20-1:50), immunocytochemistry, and immunofluorescence (at concentrations of 0.25-2 μg/mL or 1-4 μg/mL) . These applications enable researchers to investigate SLC27A3 expression patterns, subcellular localization, and potential interactions with other proteins across different experimental contexts.

What biological systems and models are most appropriate for studying SLC27A3 function?

Based on current research, several model systems have proven effective for studying SLC27A3 function. For respiratory research, cigarette smoke-exposed mice have been used as COPD models to investigate SLC27A3's role in lung inflammation and function . For cancer research, ccRCC (clear cell renal cell carcinoma) cell lines, particularly those with acquired resistance to tyrosine kinase inhibitors like pazopanib, have been valuable for studying SLC27A3's involvement in lipid metabolism and drug resistance . Human tissue samples can also be analyzed using immunohistochemistry to examine SLC27A3 expression patterns in normal versus diseased states. When selecting a model system, researchers should consider the specific pathway or disease context they aim to investigate, as SLC27A3 appears to have tissue-specific and condition-specific roles.

How does SLC27A3 expression influence inflammatory responses in respiratory diseases?

Recent research indicates that SLC27A3 plays a significant role in modulating inflammatory responses in respiratory conditions such as COPD. In COPD mouse models, elevated SLC27A3 expression in lung tissue correlates with abnormalities in lung architecture and function, imbalance between Th17 and Treg cells, and heightened inflammatory response . Mechanistically, downregulation of SLC27A3 appears to repress the JAK2/STAT3 signaling pathway, leading to decreased lung inflammation, improved Th17/Treg balance, and enhanced lung function . This suggests that SLC27A3 may serve as a regulatory node connecting lipid metabolism to inflammatory signaling in lung tissue. Researchers investigating inflammatory lung conditions should consider examining SLC27A3 expression and its downstream effects on cytokine production and immune cell differentiation.

What is the relationship between SLC27A3 expression and cancer progression or treatment resistance?

SLC27A3 has emerged as a potential factor in cancer progression and treatment resistance, particularly in lipid-rich tumors. In clear cell renal cell carcinoma (ccRCC), high SLC27A3 expression has been associated with poor prognosis . Research suggests that SLC27A3 contributes to lipid metabolic reprogramming and mitophagy in cancer cells, potentially enabling them to adapt to microenvironmental stresses and develop resistance to therapies such as tyrosine kinase inhibitors (TKIs) . Importantly, experimental knockdown of SLC27A3 has been shown to weaken tumor proliferation ability in the presence of pazopanib, a TKI used in ccRCC treatment . This indicates that SLC27A3 may serve as both a prognostic marker and a potential therapeutic target in certain cancers. Researchers studying cancer metabolism or drug resistance mechanisms should consider incorporating SLC27A3 analysis into their experimental designs.

How does SLC27A3 interact with the JAK2/STAT3 signaling pathway, and what are the implications for disease modulation?

Research has revealed a significant connection between SLC27A3 and the JAK2/STAT3 signaling pathway, which has important implications for disease progression and potential therapeutic interventions. In COPD models, SLC27A3 knockdown has been shown to repress the JAK2/STAT3 pathway, resulting in decreased inflammatory responses and improved lung function . Similarly, in cancer research, there appears to be a relationship between SLC27A3 expression, STAT signaling, and tumor cell adaptability . While the precise molecular mechanisms linking SLC27A3 to JAK2/STAT3 activation remain to be fully elucidated, this interaction represents a promising area for further investigation. Researchers interested in this connection might consider designing experiments that manipulate SLC27A3 expression levels while monitoring changes in JAK2/STAT3 phosphorylation status, downstream gene expression, and cellular phenotypes.

What role does SLC27A3 play in mitophagy and how does this impact cellular metabolism in disease states?

Emerging research suggests that SLC27A3 is involved in STAT2/SLC27A3/PINK1-mediated mitophagy, which contributes to lipid metabolic reprogramming in cancer cells . Mitophagy, the selective autophagy of mitochondria, helps maintain mitochondrial homeostasis and allows cells to adapt to changing environmental conditions. In the context of cancer, enhanced mitophagy may enable tumor cells to survive stress conditions and develop drug resistance. The molecular mechanisms through which SLC27A3 influences mitophagy likely involve its role in fatty acid transport and metabolism, which can affect mitochondrial function and integrity. Researchers investigating mitochondrial dynamics in disease states should consider examining SLC27A3 expression and its relationship to mitophagy markers such as PINK1, Parkin, and LC3-II. Experimental approaches might include mitophagy detection through electron microscopy, mitophagy-specific probes, and analysis of mitochondrial membrane potential and reactive oxygen species levels.

What are the optimal protocols for using SLC27A3 antibodies in different experimental applications?

For Western blotting, the recommended antibody concentration is 0.04-0.4 μg/mL or 0.4 μg/mL depending on the specific antibody product . Sample preparation should include proper protein extraction using a buffer compatible with membrane proteins, as SLC27A3 is a transmembrane fatty acid transporter. For immunohistochemistry on paraffin-embedded sections, an antibody dilution of 1:50-1:200 or 1:20-1:50 is recommended . Antigen retrieval is typically required, and researchers should optimize this step based on their specific tissue type. For immunofluorescence and immunocytochemistry, concentrations of 0.25-2 μg/mL or 1-4 μg/mL are suggested . Cell fixation can be performed using 4% paraformaldehyde, followed by permeabilization with 0.1-0.3% Triton X-100. In all applications, appropriate negative controls (isotype antibody or pre-immune serum) and positive controls (tissues or cells known to express SLC27A3) should be included to validate specificity.

How can researchers effectively validate SLC27A3 knockdown or overexpression in experimental models?

Validating SLC27A3 manipulation in experimental models requires a multi-level approach. At the mRNA level, quantitative RT-PCR using validated primers specific to SLC27A3 can confirm changes in gene expression following siRNA transfection or overexpression vector introduction. At the protein level, Western blotting using validated SLC27A3 antibodies provides quantitative assessment of protein abundance . Immunofluorescence or immunohistochemistry can confirm changes in protein expression while also revealing information about subcellular localization . For functional validation, assays measuring fatty acid uptake (using labeled fatty acids) or downstream metabolic processes can demonstrate the physiological impact of altered SLC27A3 expression. When developing knockout models, researchers should verify the targeting strategy using genomic PCR and sequencing to confirm the intended genetic modification. Multiple siRNA sequences or shRNA constructs targeting different regions of SLC27A3 mRNA should be tested to minimize off-target effects in knockdown experiments.

What considerations are important when designing experiments to study SLC27A3's role in specific signaling pathways?

When investigating SLC27A3's role in signaling pathways such as JAK2/STAT3, researchers should design experiments that allow for temporal analysis of pathway activation following SLC27A3 manipulation. This might involve time-course studies examining phosphorylation status of signaling intermediates after SLC27A3 knockdown or overexpression . Co-immunoprecipitation experiments can be valuable for identifying potential protein-protein interactions between SLC27A3 and components of the pathway. For more comprehensive analysis, phosphoproteomic approaches or pathway-focused array technologies might reveal broader effects of SLC27A3 on cellular signaling networks. In disease models, pharmacological inhibitors of specific pathway components can be used in conjunction with SLC27A3 manipulation to determine pathway dependency. For instance, in COPD studies, combining SLC27A3 knockdown with JAK2/STAT3 inhibitors could help establish whether the observed effects are primarily mediated through this pathway . Additionally, researchers should consider the metabolic context when studying SLC27A3 signaling, as changes in cellular fatty acid composition may indirectly affect various signaling cascades.

What are common challenges in detecting SLC27A3 using antibody-based methods, and how can they be overcome?

Several technical challenges can arise when detecting SLC27A3 through antibody-based methods. As a transmembrane protein, SLC27A3 may require optimized extraction and solubilization procedures to maintain its native conformation. For Western blotting, researchers may encounter difficulties with aggregation or degradation of the protein during sample preparation. Using fresh samples, including protease inhibitors in lysis buffers, and avoiding excessive heating can help preserve protein integrity. Non-specific binding may occur with some antibodies, necessitating careful optimization of blocking conditions and antibody dilutions. For immunohistochemistry and immunofluorescence, high background signal can be problematic. This can be addressed through extended blocking steps, use of specific blocking agents (such as normal serum matching the secondary antibody host species), and careful optimization of antibody concentration and incubation time. If detection sensitivity is an issue, signal amplification systems such as tyramide signal amplification or more sensitive detection methods may be employed. Finally, validation of antibody specificity using positive and negative controls, including SLC27A3 knockdown samples, is essential for accurate interpretation of results.

How should researchers interpret seemingly contradictory data regarding SLC27A3 function across different experimental contexts?

When faced with seemingly contradictory data regarding SLC27A3 function, researchers should consider several factors that might explain these discrepancies. First, SLC27A3 may have tissue-specific or cell type-specific functions, as evidenced by its different roles in lung inflammation versus cancer metabolism . Second, the disease context or experimental conditions may influence SLC27A3's behavior; for example, its function under normal physiological conditions might differ from its role during cellular stress or in disease states. Third, differences in experimental methodology, including the specific antibodies used, detection methods, and quantification approaches, can lead to divergent results. To reconcile contradictory findings, researchers should carefully compare experimental protocols, consider the biological context of each study, and potentially conduct side-by-side comparisons using standardized methods. Meta-analysis approaches combining data from multiple studies may help identify consistent patterns amid apparent contradictions. Finally, researchers should remain open to the possibility that SLC27A3 has multifaceted functions that vary depending on cellular context, which may explain seemingly discrepant observations across different experimental systems.

What analytical approaches are most effective for studying the relationship between SLC27A3 expression and clinical outcomes?

To effectively investigate associations between SLC27A3 expression and clinical outcomes, researchers should employ a combination of analytical approaches. For tissue-based analyses, immunohistochemistry scoring systems that account for both staining intensity and percentage of positive cells can provide semi-quantitative assessment of SLC27A3 expression . These scores can then be correlated with clinical parameters using appropriate statistical methods. RNA sequencing or qRT-PCR data from patient samples can provide quantitative expression measurements, which can be analyzed in relation to clinical outcomes using survival analysis methods such as Kaplan-Meier curves and Cox proportional hazards modeling. For more comprehensive analysis, researchers might consider multivariate models that include additional clinicopathological variables to identify independent prognostic factors. In the context of drug resistance studies, comparing SLC27A3 expression before and after treatment, or between responsive and non-responsive patients, can yield insights into its potential role as a predictive biomarker . Integration of multiple data types through approaches such as multi-omics analysis may reveal mechanistic connections between SLC27A3 expression, molecular pathways, and clinical outcomes. Finally, validation in independent patient cohorts is essential to confirm the robustness and reproducibility of any identified associations.

How can researchers effectively integrate SLC27A3 functional data with other -omics datasets to gain comprehensive insights?

Integrating SLC27A3 functional data with other -omics datasets requires a systematic multi-layered approach. Researchers can begin by examining correlations between SLC27A3 expression and global gene expression patterns through transcriptomic analysis, which may reveal co-regulated genes or affected pathways. For more direct insights into SLC27A3's impact on cellular metabolism, lipidomic and metabolomic analyses are particularly valuable, as demonstrated in studies of lipid-rich tumors where SLC27A3 influences lipid metabolism . Techniques such as micro-targeted lipidomics of acyl-CoA and comprehensive lipid profiling can identify specific metabolites associated with SLC27A3 activity. Proteomic and phosphoproteomic approaches can uncover SLC27A3-dependent changes in protein expression and post-translational modifications, particularly in signaling pathways like JAK2/STAT3 . Chromatin immunoprecipitation sequencing (ChIP-seq) targeting transcription factors associated with SLC27A3, such as STAT2, can reveal regulatory mechanisms controlling its expression . Computational integration of these multi-omics datasets through network analysis, pathway enrichment, and machine learning approaches can identify key nodes and functional modules connecting SLC27A3 to broader cellular processes. Visualization tools such as heatmaps, pathway diagrams, and interaction networks can help communicate these complex relationships effectively.